Table 3.

Results of the in vitro human cancer cell growth inhibition for selected compounds 2k, 2l, and 2o.

	Compound	2k	2l	2o			2k	2l	2o
Cell Type	Cell Line	GI% a,b (10 µM)			Cell Type	Cell Line	GI% a,b (10 µM)
Leukemia	CCRF-CEM	80	49	46	CNS Cancer	SF-295	85	20	0
	HL-60(TB)	93	19	46		SF-539	93	0	0
	K-562	84	43	42		SNB-19	59	0	20
	MOLT-4	70	40	41		SNB-75	91	0	35
	RPMI-8226	79	0	36		U251	58	0	24
	SR	66	0	0	Melanoma	M14	71	36	15
Non-Small Cell Lung Cancer	A549/ATCC	53	34	23		MDA-MB-435	88	20	35
	EKVX	65	29	25		SK-MEL-2	64	0	0
	HOP-92	56	0	0		UACC-62	58	0	38
	NCI-H226	50	35	0	Ovarian Cancer	IGROV1	60	0	19
	NCI-H460	55	0	20		OVCAR-3	63	16	34
	NCI-H522	95	39	27	Renal Cancer	786-0	50	13	17
Colon Cancer	COLO 205	59	0	0		A498	89	0	28
	HCT-116	76	40	30		ACHN	60	23	0
	HCT-15	73	45	43		CAKI-1	61	49	40
	HT29	88	42	0		RXF 393	61	27	32
	KM12	76	49	15		SN12C	66	20	23
	SW-620	65	15	27
Prostate Cancer	PC-3	71	60	45
Breast Cancer	MCF7	77	25	59
	HS 578T	62	20	0
	T-47D	70	57	43
	MDA-MB-468	88	32	60

^a Data obtained from NCI’s in vitro 60-cell one-dose screen at 10 µM concentration. ^b GI% is the percentage of growth inhibition of tumor cells.